These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 24124651)

  • 1. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
    Kim HS; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
    Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
    Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients.
    Choi BH; Ro H; Jung ES; Kim AJ; Chang JH; Lee HH; Chung W; Jung JY
    PLoS One; 2016; 11(2):e0150145. PubMed ID: 26914918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Chen YS; Yan W; Geczy CL; Brown MA; Thomas R
    Arthritis Res Ther; 2009; 11(2):R39. PubMed ID: 19284577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A; Viswanath V; Singh YP; Aggarwal A
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.
    Jung ES; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    J Korean Med Sci; 2017 Jan; 32(1):54-59. PubMed ID: 27914132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification?
    Lorenzi R; Grossin N; Lambert M; Daroux M; Adjoutah Z; Flahaut C; Jacolot P; Tessier FJ; Lefranc D; Desremaux P; Dubucquoi S; Boulanger E
    Ann Clin Biochem; 2014 Mar; 51(Pt 2):248-57. PubMed ID: 23982266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.
    Isoyama N; Machowska A; Qureshi AR; Yamamoto T; Anderstam B; Heimburger O; Barany P; Stenvinkel P; Lindholm B
    Perit Dial Int; 2016; 36(3):269-76. PubMed ID: 26493750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease.
    Zakiyanov O; Kalousová M; Kříha V; Zima T; Tesař V
    Kidney Blood Press Res; 2011; 34(6):457-64. PubMed ID: 21822023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation.
    Buhimschi IA; Zhao G; Pettker CM; Bahtiyar MO; Magloire LK; Thung S; Fairchild T; Buhimschi CS
    Am J Obstet Gynecol; 2007 Feb; 196(2):181.e1-13. PubMed ID: 17306673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes.
    Huang SM; Chang YH; Chao YC; Lin JA; Wu CH; Lai CY; Chan KC; Tseng ST; Yen GC
    Mol Nutr Food Res; 2013 Dec; 57(12):2264-8. PubMed ID: 23901023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.